By Connor Hart
Autolus Therapeutics said it received Food and Drug Administration approval of its treatment of acute lymphoblastic leukemia, or ALL, an aggressive blood and bone marrow cancer, for certain patients.
The treatment, called Aucatzyl, has been granted marketing approval for the treatment of adult patients with relapsed or refractory B-cell precursor ALL, the London biopharmaceutical company said Friday.
Its approval was based on the results of a clinical study in which 42% of patients with the cancer achieved complete remission within three months.
"Based on the experience in the Felix trial Aucatzyl is highly active and can be well managed, offering an attractive risk benefit profile for B-ALL patients," said Dr. Claire Roddie, the trial's lead investigator.
Chief Executive Christian Itin said the treatment marks Autolus' first commercial product. In addition to its U.S. approval, marketing authorization applications are being reviewed by the regulators in the European Union and the United Kingdom, the company said.
Shares rise 1.3%, to $3.78, in after-hours trading.
Write to Connor Hart at connor.hart@wsj.com
(END) Dow Jones Newswires
November 08, 2024 17:38 ET (22:38 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。